Novorapid Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid Flexpen, is an insulin analog presented as a rapid‑acting solution for subcutaneous use. It treats post‑prandial glucose spikes in people with type 1 and type 2 diabetes mellitus. GNH USA supplies Novorapid Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Novorapid Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novorapid Flexpen is a rapid‑acting insulin that works within the carbohydrate‑digestion pathway to control blood glucose levels.

- Type 1 diabetes mellitus: provides mealtime insulin coverage to lower post‑prandial glucose. - Type 2 diabetes mellitus: supplements basal insulin or oral agents for post‑meal glucose control. - Postprandial glucose control: rapidly reduces glucose excursions after meals.

Novorapid Flexpen may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Weight gain: modest increase in body weight with chronic use.

Serious or Rare Side Effects: - Severe hypoglycaemia: prolonged low blood sugar requiring assistance. - Allergic reaction: rash, hives, or swelling that may indicate anaphylaxis. - Edema: swelling of extremities due to fluid retention. - Unexplained cardiovascular events: chest pain or palpitations.

When using Novorapid Flexpen, consider the following safety measures:

- Dose titration: adjust based on blood glucose monitoring and physician guidance. - Meal timing: coordinate injection with carbohydrate intake to avoid hypoglycaemia. - Renal or hepatic impairment: monitor closely as clearance may be altered. - Pregnancy and lactation: use only if the benefits outweigh potential risks. - Storage: keep the pen refrigerated at 2‑8 °C, protect from light, and do not freeze.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Novorapid Flexpen can interact with several drug classes, requiring awareness of the interaction level.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection. - MAO‑inhibitors: can potentiate insulin’s glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides): increase risk of hypoglycaemia. - Corticosteroids: may raise blood glucose, requiring insulin dose adjustments. - Thiazide diuretics: can affect glucose tolerance and insulin sensitivity. - Alcohol: enhances insulin absorption and may precipitate hypoglycaemia.